Analysts question Karyopharm's PhIII endometrial cancer data as biotech will charge ahead to FDA
Karyopharm Therapeutics touted on Tuesday Phase III data for a cancer program it described as positive, but which Wall Street viewed in a more negative light.
The biotech reported topline results for Xpovio’s pivotal study in endometrial cancer, saying the drug reduced the risk of disease progression or death by 30% compared to placebo. Karyopharm noted the primary endpoint of median progression-free survival came in at 5.7 months for the active arm and 3.8 months in placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.